During the period 1956 to 1962, racemic
thalidomide
was marketed as a sedative and antiemetic for 'hysterical' pregnant
women. The
R enantiomer
held the desired sedative and antiemetic effects, whereas the
S enantiomer
proved to be a
teratogen.
Thalidomide
was eventually withdrawn from sale, but has returned to the market as
an anticancer drug which works by targeting angiogenesis.